AXS-05

The Neuropsychiatric Pipeline: 10 Late-Stage Therapies to Watch
BioSpace
Mon, 08/14/23 - 11:23 am
depression
Biogen
SAGE Therapeutics
zuranolone
Intra-Cellular Therapies
lumateperone
Alto Neuroscience
ALTO-100
schizophrenia
Karuna Therapeutics
KarXT
Cerevel Therapeutics
emraclidine
Acadia Pharmaceuticals
pimavanserin
Axesome Therapeutics
AXS-05
Alzheimer's agitation
NRx
NRX-101
bipolar disorder
Biohaven
troriluzole
OCD
VistaGen
fasedienol
social anxiety
Axsome says FDA wants more data for Alzheimer’s agitation label expansion, but readout to come sooner 
Endpoints
Mon, 02/27/23 - 10:19 am
Axsome Therapeutics
FDA
clinical trials
Alzheimer's disease agitation
Alzheimer's disease
AXS-05
Axsome Headed to FDA after Phase III Alzheimer's Agitation Win
BioSpace
Mon, 11/28/22 - 10:23 am
Axsome Therapeutics
clinical trials
Alzheimer's disease
Alzheimer's agitation
AXS-05
Axsome moves 'closer to judgement day' for stalled depression therapy
Fierce Biotech
Tue, 04/19/22 - 11:05 am
Axsome Therapeutics
FDA
depression
AXS-05
Why Axsome Therapeutics Is Plunging Again Tuesday
Motley Fool
Tue, 08/10/21 - 11:14 pm
Axsome Therapeutics
FDA
AXS-05
Letter from FDA outlining deficiencies for lead drug causes Axsome stock to crater. Is a CRL on the way?
Endpoints
Mon, 08/9/21 - 11:02 am
Axsome
major depressive disorder
FDA
AXS-05
FDA Begins Priority Review of Axsome Therapeutics' Potential New Depression Drug
Motley Fool
Mon, 04/26/21 - 11:07 pm
Axsome Therapeutics
depression
AXS-05
Aducanumab tops 2021’s biggest potential launches
EP Vantage
Mon, 01/18/21 - 01:04 pm
drug launches
Biogen
Eisai
aducanumab
efgartigimod
Argenx
Evrenzo
FibroGen
Astellas
AstraZeneca
Leqvio
Novartis
UCB Pharma
bimekizumab
Ascendis Pharma
Bluebird Bio
Bristol-Myers Squibb
ide-cel
liso-cel
AXS-05
Axsome Therapeutics
voclosporin
Aurinia
Presented with upbeat Alzheimer's agitation data, FDA sees another 'breakthrough' in Axsome's AXS-05
Endpoints
Sat, 06/27/20 - 11:37 pm
Axsome Therapeutics
Alzheimer's disease
AXS-05
major depressive disorder
There May Be a New First-Line Treatment for Depression
Motley Fool
Thu, 04/30/20 - 10:37 am
Axsome Therapeutics
FDA
depression
AXS-05
Axsome shares rocket up on a surprise win for late-stage Alzheimer’s agitation study — but this is no easy layup
Endpoints
Mon, 04/27/20 - 09:42 am
Axsome Therapeutics
Alzheimer's disease
clinical trials
FDA
AXS-05
Axsome celebrates migraine PhIII win, shifting eyes toward a pair of Q4 submissions
Endpoints
Mon, 04/6/20 - 10:36 am
Axsome
clinical trials
migraines
AXS-05
Axsome Therapeutics' Key Drug Candidate Whiffs in Phase 3 Trial
Motley Fool
Mon, 03/30/20 - 08:15 pm
Axsome Therapeutics
AXS-05
treatment-resistant depression
clinical trials
How Big of a Deal Is Axsome Therapeutics' New Depression Drug?
Motley Fool
Wed, 12/18/19 - 11:51 pm
Axsome Therapeutics
AXS-05
major depressive disorder
3 Biotech Stocks With Big Incoming Catalysts
Motley Fool
Mon, 12/16/19 - 10:52 am
Axsome Therapeutics
AXS-05
Solid Biosciences
SGT-001
Duchenne Muscular Dystrophy
major depressive disorder
Intra-Cellular Therapies
lumateperone
schizophrenia
Axsome’s Depression Drug Meets Phase 3 Goals, FDA Filing Planned
Xconomy
Mon, 12/16/19 - 10:38 am
Axsome Therapeutics
AXS-05
major depressive disorder
clinical trials
Upcoming events – Axsome’s depression data and Eli Lilly’s IL-10 in lung cancer
EP Vantage
Fri, 12/13/19 - 11:02 am
Axsome Therapeutics
AXS-05
treatment-resistant depression
depression
Eli Lilly
pegilodecakin
lung cancer
Axsome's AXS-05 Helps Patients Quit Smoking Significantly in Phase II Trial
BioSpace
Tue, 04/16/19 - 10:50 am
Axsome Therapeutics
smoking cessation
AXS-05
bupropion
3 Leading Alzheimer's Disease Drugs in Development After Biogen's Aducanumab Flop
Motley Fool
Sat, 03/30/19 - 12:44 pm
Alzheimer's disease
Biogen
aducanumab
Otsuka
Axsome Therapeutics
Amgen
Novartis
Avanir
AVP-786
AXS-05
AMG520
2 Biotech Stocks With Major Incoming Catalysts
Yahoo/Motley Fool
Thu, 03/7/19 - 09:52 am
Axsome Therapeutics
AXS-05
depression
Galapagos
filgotinib
Gilead Sciences
rheumatoid arthritis